JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

The Prognostic and Early Efficacy Prediction Value of Baseline C-Reactive Protein-Albumin-Lymphocyte (CALLY) Index in Advanced Pancreatic Cancer

  • 0Department of Oncology, Nanjing Gaochun People's Hospital, Nanjing, 211300, People's Republic of China.
International Journal of General Medicine +

|

June 30, 2025

|

June 30, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

The CALLY index can predict treatment effectiveness and prognosis in advanced pancreatic cancer patients. A higher CALLY index indicates better survival outcomes and treatment response.

Area Of Science

  • Oncology
  • Biomarker Research
  • Clinical Diagnostics

Background

  • Advanced pancreatic cancer has a poor prognosis.
  • Predictive biomarkers are crucial for optimizing treatment strategies.

Purpose Of The Study

  • To evaluate the prognostic and early efficacy prediction value of the CALLY index in advanced pancreatic cancer.
  • To determine the optimal cut-off for the CALLY index.

Main Methods

  • Retrospective analysis of 252 metastatic pancreatic cancer patients.
  • ROC curve analysis to determine the optimal CALLY index cut-off.
  • Kaplan-Meier and Cox regression models for survival analysis.
  • RECIST 1.1 criteria for early efficacy assessment.

Main Results

  • The optimal CALLY index cut-off for survival prediction was 0.27 (AUC=0.725).
  • Patients with CALLY index ≥0.27 had significantly better overall survival (median 12 vs 5 months, P < 0.01).
  • A CALLY index of 0.27 also predicted early treatment efficacy (AUC=0.73, P=0.022).

Conclusions

  • The baseline CALLY index is a potential predictive biomarker for prognosis and early treatment efficacy in advanced pancreatic cancer.
  • Further validation in multicenter prospective studies is recommended.

Keywords: